Combined Treatment with the Mood Stabilizers Lithium and Valproate Produces Multiple Beneficial Effects in Transgenic Mouse Models of Huntington's Disease

被引:107
作者
Chiu, Chi-Tso [1 ]
Liu, Guangping [1 ]
Leeds, Peter [1 ]
Chuang, De-Maw [1 ]
机构
[1] NIMH, Mol Neurobiol Sect, NIH, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
Huntington's disease; lithium; valproate; GSK-3; HDACs; transgenic mouse model; GLYCOGEN-SYNTHASE KINASE-3; TAIL SUSPENSION TEST; HISTONE DEACETYLASE INHIBITORS; STRIATAL NEURONAL LOSS; REDUCES BRAIN-DAMAGE; FORCED-SWIM TEST; NEUROTROPHIC FACTOR; INTRANUCLEAR INCLUSIONS; MOLECULAR-MECHANISMS; CORTICAL-NEURONS;
D O I
10.1038/npp.2011.128
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Emerging evidence suggests that the mood stabilizers lithium and valproate (VPA) have broad neuroprotective and neurotrophic properties, and that these occur via inhibition of glycogen synthase kinase 3 (GSK-3) and histone deacetylases (HDACs), respectively. Huntington's disease (HD) is an inherited neurodegenerative disorder characterized by impaired movement, cognitive and psychiatric disturbances, and premature death. We treated N171-82Q and YAC128 mice, two mouse models of HD varying in genetic backgrounds and pathological progressions, with a diet containing therapeutic doses of lithium, VPA, or both. Untreated, these transgenic mice displayed a decrease in levels of GSK-3 beta serine 9 phosphorylation and histone H3 acetylation in the striatum and cerebral cortex around the onset of behavioral deficits, indicating a hyperactivity of GSK-3 beta and HDACs. Using multiple well-validated behavioral tests, we found that co-treatment with lithium and VPA more effectively alleviated spontaneous locomotor deficits and depressive-like behaviors in both models of HD mice. Furthermore, compared with monotherapy with either drug alone, co-treatment more successfully improved motor skill learning and coordination in N171-82Q mice, and suppressed anxiety-like behaviors in YAC128 mice. This combined treatment consistently inhibited GSK-3 beta and HDACs, and caused a sustained elevation in striatal as well as cortical brain-derived neurotrophic factor and heat shock protein 70. Importantly, co-treatment markedly prolonged median survival of N171-82Q mice from 31.6 to 41.6 weeks. Given that there is presently no proven treatment for HD, our results suggest that combined treatment with lithium and VPA, two mood stabilizers with a long history of safe use in humans, may have important therapeutic potential for HD patients. Neuropsychopharmacology (2011) 36, 2406-2421; doi:10.1038/npp.2011.128; published online 27 July 2011
引用
收藏
页码:2406 / 2421
页数:16
相关论文
共 94 条
[1]   Role of GSK3β in behavioral abnormalities induced by serotonin deficiency [J].
Beaulieu, Jean-Martin ;
Zhang, Xiaodong ;
Rodriguiz, Ramona M. ;
Sotnikova, Tatyana D. ;
Cools, Michael J. ;
Wetsel, William C. ;
Gainetdinov, Raul R. ;
Caron, Marc G. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (04) :1333-1338
[2]   Brain-derived neurotrophic factor-mediated protection of striatal neurons in an excitotoxic rat model of Huntington's disease, as demonstrated by adenoviral gene transfer [J].
Bemelmans, AP ;
Horellou, P ;
Pradier, L ;
Brunet, I ;
Colin, P ;
Mallet, J .
HUMAN GENE THERAPY, 1999, 10 (18) :2987-2997
[3]   Lithium's effect in forced-swim test is blood level dependent but not dependent on weight loss [J].
Bersudsky, Yuly ;
Shaldubina, Alona ;
Belmaker, R. H. .
BEHAVIOURAL PHARMACOLOGY, 2007, 18 (01) :77-80
[4]   Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3) [J].
Beurel, Eleonore ;
Michalek, Suzanne M. ;
Jope, Richard S. .
TRENDS IN IMMUNOLOGY, 2010, 31 (01) :24-31
[5]   Short and long-term motor skill learning in an accelerated rotarod training paradigm [J].
Buitrago, MM ;
Schulz, JB ;
Dichgans, J ;
Luft, AR .
NEUROBIOLOGY OF LEARNING AND MEMORY, 2004, 81 (03) :211-216
[6]   Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease [J].
Canals, JM ;
Pineda, JR ;
Torres-Peraza, JF ;
Bosch, M ;
Martín-Ibañez, R ;
Muñoz, MT ;
Mengod, G ;
Ernfors, P ;
Alberch, J .
JOURNAL OF NEUROSCIENCE, 2004, 24 (35) :7727-7739
[7]   Glycogen synthase kinase-3β inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation [J].
Carmichael, J ;
Sugars, KL ;
Bao, YP ;
Rubinsztein, DC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (37) :33791-33798
[8]  
Carter RJ, 1999, J NEUROSCI, V19, P3248
[9]   Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons [J].
Chalecka-Franaszek, E ;
Chuang, DM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (15) :8745-8750
[10]   Mechanisms of chaperone suppression of polyglutamine disease:: selectivity, synergy and medullation of protein solubility in Drosophila [J].
Chan, HYE ;
Warrick, JM ;
Gray-Board, GL ;
Paulson, HL ;
Bonini, NM .
HUMAN MOLECULAR GENETICS, 2000, 9 (19) :2811-2820